Chengdu Olymvax Biopharmaceuticals Inc.

Chengdu Olymvax Biopharmaceuticals Inc. specializes in the research, development, and distribution of vaccines. Their current product portfolio includes immunizations against tetanus, a severe and often fatal infectious disease that damages the nervous system due to toxins produced by Clostridium tetani, alongside a vaccine for Haemophilus influenzae type b. Beyond their existing offerings, the company is actively advancing new vaccine candidates targeting Staphylococcus aureus, a prevalent bacterium responsible for both hospital-acquired and community infections, and illnesses associated with Group A streptococcus. This enterprise was established in 2009 and operates from its base in Chengdu, China.